J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP 4

Accession 0001125282-04-001878

CIK 0001173657other

View on SEC.gov Company Profile

Filed

Apr 29, 8:00 PM ET

Accepted

Apr 30, 6:52 PM ET

Size

59.9 KB

Accession

0001125282-04-001878

Insider Transaction Report

Form 4

Period: 2004-04-28

BARRIER THERAPEUTICS INCBTRX

JP MORGAN PARTNERS BHCA LP

10% Owner

Transactions

Conversion
Common Stock
2004-04-28+22,483→ 22,483 total(indirect: See Footnote)
Conversion
Series B Convertible Preferred Stock
2004-04-28−665,744→ 0 total(indirect: See Footnote)
From: 2004-04-28→ Common Stock (332,872 underlying)
Conversion
Series C Convertible Preferred Stock
2004-04-28−65,370→ 0 total(indirect: See Footnote)
From: 2004-04-28→ Common Stock (32,685 underlying)
Conversion
Series C Convertible Preferred Stock
2004-04-28−20,007→ 0 total(indirect: See Footnote)
From: 2004-04-28→ Common Stock (10,003 underlying)
Conversion
Common Stock
2004-04-28+397,975→ 397,975 total(indirect: See Footnote)
Conversion
Series B Convertible Preferred Stock
2004-04-28−4,201,280→ 0 total
From: 2004-04-28→ Common Stock (2,100,640 underlying)
Conversion
Series B Convertible Preferred Stock
2004-04-28−37,657→ 0 total(indirect: See Footnote)
From: 2004-04-28→ Common Stock (18,828 underlying)
Conversion
Series C Convertible Preferred Stock
2004-04-28−740,321→ 0 total
From: 2004-04-28→ Common Stock (370,160 underlying)
Conversion
Series C Convertible Preferred Stock
2004-04-28−7,310→ 0 total(indirect: See Footnote)
From: 2004-04-28→ Common Stock (3,655 underlying)
Conversion
Common Stock
2004-04-28+55,380→ 55,380 total(indirect: See Footnote)
Conversion
Series C Convertible Preferred Stock
2004-04-28−130,207→ 0 total(indirect: See Footnote)
From: 2004-04-28→ Common Stock (65,103 underlying)
Conversion
Common Stock
2004-04-28+2,470,800→ 2,470,800 total
Conversion
Common Stock
2004-04-28+201,635→ 201,635 total(indirect: See Footnote)
Conversion
Series B Convertible Preferred Stock
2004-04-28−337,900→ 0 total(indirect: See Footnote)
From: 2004-04-28→ Common Stock (168,950 underlying)
Conversion
Series B Convertible Preferred Stock
2004-04-28−90,754→ 0 total(indirect: See Footnote)
From: 2004-04-28→ Common Stock (45,377 underlying)

Footnotes (5)

[F1]The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P.
[F2]The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P.
[F3]The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P.
[F4]The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman) II, L.P.
[F5]The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis.

Documents

2 files

Issuer

BARRIER THERAPEUTICS INC

CIK 0001173657

→

Entity typeother

Related Parties

filerCIK 0001169889

Filing Metadata

Form type: 4
Filed: Apr 29, 8:00 PM ET
Accepted: Apr 30, 6:52 PM ET
Size: 59.9 KB

View on SEC.gov